Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us
PO Box 3787

South Brisbane QLD 4101

A/Prof Louise Nott

BMedSci, MBBS(Hons), FRACP

  • Medical Oncologist

Biography

A/Prof Louise Nott is passionate about delivering the best possible outcomes for all her patients. Through years of experience, she has gained an extensive knowledge base and an ability to confidently communicate with patients and families. Her work commitment and attention to detail reassures patients they are in the best hands. She is a strong advocate for clinical trials and local research, ensuring Tasmanian patients have access to the latest treatment options closer to home.

Clinical Associate Professor Louise Nott is an experienced medical oncologist at Icon Cancer Centre Hobart. She completed her Bachelor of Medicine, Bachelor of Surgery (Honours) at the University of Tasmania and became a fellow of the Royal Australasian College of Physicians (FRACP) in 2006. A/Prof Nott undertook a fellowship at The Queen Elizabeth Hospital in Adelaide before returning to Hobart in 2007 to work as a medical oncology staff specialist at Royal Hobart Hospital.

A/Prof Nott is widely published and has acted as principal and sub investigator on over 50 oncology clinical trials across industry, collaborative and academic sectors. She holds an honorary associate position at Sydney Medical School and is a university associate with the Menzies Research Institute in Tasmania. A/Prof Nott has extensive experience in treating a wide variety of cancers and is dedicated to providing excellence in cancer care for her patients and their loved ones.

She is also Icon Group’s Director of Medical Oncology (AU/NZ) providing exceptional clinical leadership across Icon’s Australia and New Zealand centres.

Research

Trials being conducted by this doctor

SYMBIOTIC GI-03 / C6461003

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before.To join the study, participants must meet the following conditions:Be 18 years or older.Have colorectal cancer that has spread to other parts of your body.Be in good enough health to receive study treatment.Should not be pregnant before starting treatment.Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects.The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment.The study is expected to last approximately 33 months for each participant.Participants will have regular visits to the study site for treatment, health checks, and tests.After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects.Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.

Locations Hobart, Wesley

Diagnosis Colorectal cancer

See all trials by A/Prof Louise Nott